Enzalutamide Plus ADT Significantly Reduces Risk of Progression in Metastatic Hormone-Sensitive…

A new study has found that enzalutamide given with androgen deprivation therapy significantly reduced the risk of metastatic progression or death in men with metastatic hormone-sensitive prostate cancer versus placebo plus ADT, including patients with low-volume disease and/or prior docetaxel therapy.

Read the full article here

Related Articles